Gastrointestinal Microbiome Clinical Trial
NCT number | NCT02867605 |
Other study ID # | 16-142 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | June 20, 2019 |
Verified date | August 2020 |
Source | The Cleveland Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate whether oral HA35 supplementation changes the normal intestinal bacteria, increases intestinal protection, decrease intestinal inflammation and permeability, and to assess any health benefits and confirm the safety profile of HA35.
Status | Completed |
Enrollment | 20 |
Est. completion date | June 20, 2019 |
Est. primary completion date | September 20, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - BMI 19-25 (lean), and BMI 30-35 (obese) - Age 18-45 years old - Willingness to take oral supplement and adhere to study requirements Exclusion Criteria: - Diabetes - Oral antibiotics within 4 weeks of study initiation - History of cardiac disease, and medications for cardiac disease - Use statins and antihypertensive drugs - Inflammatory bowel disease including irritable bowel syndrome - History of intestinal surgery, excluding hernia repair and appendectomy - Active cancer diagnosis (except skin cancer) - Chronic acid suppression treatment (proton pump inhibitors, histamine H2 receptor antagonists) - Immune modulatory treatments (e.g. chronic immunosuppressive medications, chronic NSAIDs) - Vegetarian or vegan diet7 - Abnormal liver or kidney function as measured by routine serum chemistry testing - Severe anemia or significant white blood cell or platelet abnormalities - No additional blood or blood product donations during the study |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
The Cleveland Clinic |
United States,
Hill DR, Kessler SP, Rho HK, Cowman MK, de la Motte CA. Specific-sized hyaluronan fragments promote expression of human ß-defensin 2 in intestinal epithelium. J Biol Chem. 2012 Aug 31;287(36):30610-24. doi: 10.1074/jbc.M112.356238. Epub 2012 Jul 3. — View Citation
Hill DR, Rho HK, Kessler SP, Amin R, Homer CR, McDonald C, Cowman MK, de la Motte CA. Human milk hyaluronan enhances innate defense of the intestinal epithelium. J Biol Chem. 2013 Oct 4;288(40):29090-104. doi: 10.1074/jbc.M113.468629. Epub 2013 Aug 15. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composition of Stool Micro Biome Diversity and Phylogenetic Distribution at 0 Days, 8 Days and 28 Days | Relative abundance is defined as the proportion of total identified bacteria in a sample that are a given type of bacteria. As an example a relative abundance of firmicutes equal to 0.9 would mean that 90% of the bacteria identified in a sample are firmicutes | Baseline, Day 8, Day 28 | |
Primary | Laboratory Parameters at Day 0, Day 8 and 28 Calcium, Bilirubin, Glucose, Blood Urea Nitrogen, Creatinine | Baseline, Day 8, Day 28 | ||
Primary | Indirect Calorimetry Data at 0 Day, 8 Days and 28 Days Volume of Oxygen and Volume Carbon Dioxide | Baseline, Day 8, Day 28 | ||
Primary | Indirect Calorimetry Data at 0 Day, 8 Days and 28 Days Respiratory Quotient RQ | The respiratory quotient is a ratio between the volume of carbon dioxide exhaled and the volume of oxygen inhaled during respiration. It typically ranges between 0.7 and 1.0 and is an indicator of metabolic fuel or substrate use in tissues; it must be calculated under resting or steady-state exercise conditions. A ratio of 0.7 is indicative of mixed fat use, whereas a ratio of 1.0 indicates the exclusive use of carbohydrates | Baseline, Day 8, Day 28 | |
Primary | Fecal Intestinal Antimicrobial Peptide Secretion at 0 Days, 8 Days and 28 Days Total Protein | Baseline, Day 8, Day 28 | ||
Primary | Fecal Intestinal Antimicrobial Peptide Secretion at 0 Days, 8 Days and 28 Days Normalized Calprotectin and Human Beta-Defensin2 | Baseline, Day 8, Day 28 | ||
Primary | Serum Indicators of Intestinal Permeability at 0 Days, 8 Days and 28 Days Serum Lipopolysaccharide, Hyaluronan | Baseline, Day 8, Day 28 | ||
Primary | Serum Indicators of Inflammation and Injury at Baseline, 8 Days and 28 Days-tumor Necrosis Factor (TNF) Alpha, Interleukin 6 (IL-6) | Baseline, Day 8, Day 28 | ||
Primary | Baseline Serum Indicators of Inflammation and Injury at Baseline, 8 Days and 28 Days-C-reactive Protein | Baseline, Day 8, Day 28 | ||
Primary | Blood Protein, Hemoglobin and Albumin Levels at Baseline, Day 8, and Day 28 | Baseline, day 8 day 28 | ||
Primary | White Blood Cell and Platelet Count at Baseline, Day 8, and Day 28 | baseline, day 8, and day 28 | ||
Primary | Alkaline Phosphatase, Alanine Transaminase , and Aspartate Transaminase at Baseline, Day 8, and Day 28 | baseline, day 8, and day 28 | ||
Primary | Serum Sodium, Potassium, and Carbon Dioxide at Baseline Day 8 and Day 28 | baseline, day 8, and day 28 | ||
Primary | Resting Energy Expenditure (REE) and Metabolic Rate at Baseline Day 8 an Day 28 | Baseline, day 8, and day 28 | ||
Primary | Resting Energy Expenditure as a Percent of Predicted at Baseline, Day 8, and Day 28 | This values measures the amount of energy a person uses during rest and compares it the average expected number of someone who is the same gender, age, and race. | Baseline, day 8, and day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05371704 -
The Effect of Micronutrient Supplementation on Gut Microbiome Composition and Function
|
N/A | |
Recruiting |
NCT05961189 -
Influence of Short-Term Antibiotic Therapy on Exercise
|
Early Phase 1 | |
Not yet recruiting |
NCT06126094 -
Benefits of Alcoholic Hangover Medicine
|
N/A | |
Completed |
NCT06087146 -
Modulation of the Gut Microbiota of Professional Athletes With Sauerkraut Supplementation
|
N/A | |
Not yet recruiting |
NCT05364736 -
Effect of Prebiotics on Blood Pressure Management
|
N/A | |
Completed |
NCT03949543 -
The Timing of Main Meal Consumption Effect on Gut Microbiota and Host
|
N/A | |
Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|
||
Completed |
NCT02998177 -
Characterization of Rebound Pain Following Peripheral Nerve Block and Its Association With Gut Microbiome Diversity
|
N/A | |
Recruiting |
NCT05657730 -
Study the Effect of Water Kefir Consumption on the Gut Microbiome in Healthy Adults
|
N/A | |
Active, not recruiting |
NCT03978104 -
Impact of Okara and Bio-okara Food Product on Gut and Glycaemic Health in Middle-aged and Older Adults in Singapore
|
N/A | |
Terminated |
NCT04059666 -
Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas
|
N/A | |
Completed |
NCT04088474 -
Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora
|
N/A | |
Not yet recruiting |
NCT06332898 -
The Effects of a Nutritional Supplement on Nutrient Status and Quality of Life
|
N/A | |
Completed |
NCT04046432 -
Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative Capacity
|
N/A | |
Completed |
NCT05729269 -
Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass
|
||
Recruiting |
NCT05692024 -
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06207136 -
Microbiome and Diet in Parkinson's Disease
|
N/A | |
Recruiting |
NCT03812445 -
Cognition and Gut Microbiome Associated Study of Shanghai People With Acute Ischemic Stroke
|
N/A | |
Not yet recruiting |
NCT04947930 -
Fecal Metagenomics and Metabolomics Analyses to Identify Potential Screening Biomarkers for Colorectal Polyps and Cancer in Chinese Population
|
||
Recruiting |
NCT04031469 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
|